September 1997
Volume 38, Issue 10
Free
Articles  |   September 1997
Topical formulations of novel angiostatic steroids inhibit rabbit corneal neovascularization.
Author Affiliations
  • D BenEzra
    Department of Ophthalmology, Hadassah University Hospital, Jerusalem, Israel.
  • B W Griffin
    Department of Ophthalmology, Hadassah University Hospital, Jerusalem, Israel.
  • G Maftzir
    Department of Ophthalmology, Hadassah University Hospital, Jerusalem, Israel.
  • N A Sharif
    Department of Ophthalmology, Hadassah University Hospital, Jerusalem, Israel.
  • A F Clark
    Department of Ophthalmology, Hadassah University Hospital, Jerusalem, Israel.
Investigative Ophthalmology & Visual Science September 1997, Vol.38, 1954-1962. doi:
  • Views
  • PDF
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      D BenEzra, B W Griffin, G Maftzir, N A Sharif, A F Clark; Topical formulations of novel angiostatic steroids inhibit rabbit corneal neovascularization.. Invest. Ophthalmol. Vis. Sci. 1997;38(10):1954-1962.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

PURPOSE: To evaluate the antiangiogenic potential of topical ophthalmic formulations of the novel angiostatic steroids AL-3789 and AL-4940, using a rabbit model of corneal neovascularization. METHODS: Neovascularization was induced in the rabbit cornea by surgical implantation of a standard ethylene vinyl acetate copolymer (Elvax-40) pellet containing 1 microg lipopolysaccharide. Coded formulations of the control vehicle or the following test agents were administered in prevention and intervention treatment protocols: 1% formulations of AL-3789, AL-4940, and cortisol acetate as a positive drug control. Three doses of AL-3789 (0.01%, 0.1%, and 1%) were also evaluated in a prevention treatment protocol. Corneal responses were monitored throughout a 2-week treatment period, and 1 week after the last treatment dose. Observations included quantitative measurement of the area of new blood vessel growth and qualitative assessment of cellular infiltrate and edema. All treatments and observations were performed in a double-masked manner. RESULTS: All tested formulations, except the vehicle and the 0.01% AL-3789 preparation, significantly inhibited corneal neovascularization and other lipopolysaccharide-induced responses in the various treatment protocols employed. AL-4940, the free alcohol form of AL-3789, was slightly less effective than cortisol acetate or AL-3789. The extent of inhibition of the angiogenic response by the 1% and 0.1% AL-3789 suspensions ranged from 76% to 100% 1 week after the last treatment. CONCLUSIONS: The antiangiogenic steroid AL-3789 may be a therapeutically useful angiostatic agent for corneal neovascularization and potentially could be effective in other ocular neovascular diseases.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×